Ligand Pharmaceuticals’ Post

Read our article in the European Biopharmaceutical Review (EBR) to learn more about how Just - Evotec Biologics is bringing #continuousbiomanufacturing to Europe.

Optimisation of workflows is what we do at Genovis - this is yet another example - now with a RNAase inhibitor in collaboration with SEQURNA AB #genovis #RNAaseinhibitor

Full scope... full solution... fully appreciating and anticipating the expectations and needs of our customers. That's what KBI Biopharma is all about. Today marks a pivotal point in our corporate journey. We can now carry through the productivity and quality of our projects to the end point - in a streamlined fashion. #cdmo #endtoendsolutions #onestopshop #contractmanufacturing #processdevelopment #fillfinish #downstreamprocessing

In this exclusive guidebook, discover the journey of a molecule & how it's built to serve. Merck experts share key considerations for biopharmaceutical companies as they advance their antibody drug to commercial manufacturing, plus more. Don't miss out! Learn More>> https://hubs.li/Q02NRXZg0 Sponsored by Merck

In case you missed it! Following the addition of StemSight - Vision Unlimited to our family of licensees earlier this year, our CEO, John E. Milad, and StemSight’s CCO, Ross Macdonald, discuss how #CRISPRCas9 has become a transformative tool in life sciences. If you haven’t already, read our latest article in European Biopharmaceutical Review (EBR): https://shorturl.at/0dgFD

The biopharmaceutical industry is constantly evolving, with the demand for complex biologics on the rise. To stay competitive, companies must navigate the complexities of biopharmaceutical development while managing costs effectively. One key strategy for achieving this balance is partnering with Contract Development and Manufacturing Organizations (CDMOs). In this article, we will explore the role of CDMOs in cutting costs and discuss the strategies they employ to achieve this goal. https://lnkd.in/eJGW9DGh

The FTC and DOJ have increasingly focused on the impact that life sciences M&A could have on “nascent competition,” which is competition that might eventually exist between therapies already on the market and those in early-stage development. The Agencies have even gone so far as to oppose deals involving investigational therapies in as early as phase 1 clinical trials – which can be nearly a decade away from reaching the market, if at all. By continuing to pursue this approach, the Agencies are jeopardizing a vital pathway for biopharmaceutical companies to be able to bring early-stage therapies to patients. Read more: https://lnkd.in/e_Vdi-W9

1. Algorae Pharmaceuticals launched Version 1.0 of its biopharmaceutical platform, AlgoraeOS, at the University of New South Wales. 2. AlgoraeOS aggregates data on over 5,000 drugs and molecules across 150 human cell types. 3. The platform utilizes AI to predict fixed-dose combination (FDC) drugs for potential clinical trials, either independently or with partners. 4. FDCs combine two or more active ingredients, potentially enhancing efficacy and reducing side effects. 5. Algorae aims to develop new therapies while minimizing the costs and time associated with discovering new molecular entities. 6. FDCs can benefit from accelerated development pathways with regulatory agencies, leading to easier patenting opportunities. 7. AlgoraeOS has shown high correlation coefficients (0.91 – 0.98) in predicting drug synergy based on its training data. 8. AlgoraeOS is hosted on the Gadi supercomputer, offering significant computational capacity for drug prediction.

We are often asked about the advantages of using AdvantaFlex TPE tubing - here is a handy blog post on exactly why you should consider using this tubing in your process..